Lawsuit filed for Investors who lost money with shares of Ventyx Biosciences, Inc. (NASDA: VTYX)

An investor, who purchased shares of Ventyx Biosciences, Inc. (NASDA: VTYX), filed a lawsuit over alleged violations of Federal Securities Laws by Ventyx Biosciences, Inc. in connection with certain allegedly false and misleading statements.

Investors who purchased shares of Ventyx Biosciences, Inc. (NASDA: VTYX) have certain options and for certain investors are short and strict deadlines running. Deadline: April 30, 2024. NASDA: VTYX investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

San Diego, CA based Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases.
On October 21, 2021, Ventyx Biosciences, Inc issued numerous press releases containing positive news and results from its development of VTX958, a novel TYK2 inhibitor.
On November 6, 2023, Ventyx Biosciences, Inc issued a press release announcing results from its Phase 2 SERENITY Trial. The Company disclosed that "[a]lthough the trial achieved its primary endpoint, the magnitude of efficacy observed did not meet our internal target to support the advancement of VTX958 in plaque psoriasis." Based on these results, the Company announced that it "will terminate ongoing activities in the Phase 2 plaque psoriasis trial effective immediately" and "terminate the ongoing Phase 2 trial of VTX958 in psoriatic arthritis."

Shares of Ventyx Biosciences, Inc. reported that its (NASDA: VTYX) declined from $46.71 per share on March 07, 2023, to as low as $1.87 per share on January 18, 2024.

The plaintiff claims that between October 21, 2021 and November 6, 2023, Ventyx Biosciences, Inc. failed to disclose that VTX958 was less effective in treating psoriasis than the Company had led investors to believe, that as a result, VTX958's clinical and/or commercial prospects were overstated, that accordingly, the Company had misrepresented its ability to develop and commercialize effective product candidates, that Ventyx's post-IPO business prospects were thus inflated, and that as a result, the Company's public statements were materially false and misleading at all relevant times.

Those who purchased shares of Ventyx Biosciences, Inc. (NASDA: VTYX) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.